|
Botulinum toxin type A for prophylactic treatment of chronic migraine |
Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G, Samuelsson O |
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kim M, Danielsson A, Ekelund A-C, Kemppainen E, Sjögren P, Svanberg T, Szalo G, Samuelsson O. Botulinum toxin type A for prophylactic treatment of chronic migraine. Gothenburg: The Regional Health Technology Assessment Centre (HTA-centrum). HTA-rapport 2014:70. 2014 Authors' conclusions It is uncertain whether BTX reduces the frequency of headache days, reduces acute headache pain medication, or has any impact on functioning in comparison with saline. Botulin toxin A injection may result in little or no difference in the number of headache episodes, headache hours and quality of life in comparison to saline injections.
It cannot be excluded that saline injections per se have beneficial effects on chronic migraine.
The effects of repeated BTX injections during more than one year follow-up are not known.
Indexing Status Subject indexing assigned by CRD MeSH Botulinum Toxins, Type A; Humans; Migraine Disorders; Neuromuscular Agents Language Published English Country of organisation Sweden English summary An English language summary is available. Address for correspondence The Regional Health Technology Assessment Centre, Region Vastra Gotaland, HTA-centrum, Roda Straket 8, Sahlgrenska Universitetssjukhuset, 413 45 GOTHENBORG, Sweden Email: hta-centrum@vgregion.se AccessionNumber 32016000590 Date abstract record published 29/03/2016 |
|
|
|